Sarcomas | Specialty

The sarcomas/tgct condition center is a comprehensive resource for clinical news and expert insights on sarcomas/tgct. Read more at OncLive.

Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis

December 24th 2024

Panelists discuss how synovial sarcoma is a rare soft-tissue cancer characterized by its unique SS18::SSX fusion oncogene transcript, which distinguishes it from other sarcomas and drives its aggressive behavior through altered epigenetic regulation, despite its misleading name suggesting origin in synovial tissue.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

Translating Metabolic Therapies Into Sarcoma

December 18th 2024

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Dr D'Angelo on the Significance of Lete-Cel Treatment Across Sarcoma Subtypes

December 17th 2024

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

December 5th 2024

R. Lor Randall, MD, FACS, discusses advancements in preclinical research identifying therapeutic vulnerabilities in soft tissue sarcomas.

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

November 25th 2024

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

November 12th 2024

The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

November 12th 2024

Pimicotinib improved responses compared with placebo in tenosynovial giant cell tumor.

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

November 11th 2024

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.

Dr Randall on the Effect of Socioeconomic Factors in Pediatric Nonmetastatic Osteosarcoma

November 5th 2024

R. Lor Randall, MD, FACS, discusses the impact of race, ethnicity, and socioeconomic factors on outcomes in pediatric patients with nonmetastatic osteosarcoma.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.

The OncFive: Top Oncology Articles for the Week of 10/27

November 2nd 2024

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Botensilimab Plus Balstilimab Elicits Durable Responses in Refractory Metastatic Sarcoma

October 18th 2024

Breelyn Wilky, MD, discusses updated efficacy and safety findings following treatment of botensilimab and balstilimab in refractory metastatic sarcoma.

Dr Martín-Broto on the Efficacy of Sunitinib Plus Nivolumab in Clear Cell Sarcoma

October 8th 2024

Javier Martín Broto MD, PhD, discusses the efficacy of treatment with sunitinib plus nivolumab in clear cell sarcoma, according to the IMMUNOSARC II trial.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress

September 25th 2024

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

LP-184 Earns 3 FDA Rare Pediatric Disease Designations Across Ultra-Rare Tumor Types

September 24th 2024

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

Non-Hispanic Black Children Experience Inferior Post-Relapse Survival Outcomes vs Whites With Nonmetastatic Osteosarcoma

September 19th 2024

R. Lor Randall, MD, FACS, discusses the relationship between poverty, race, ethnicity, and survival outcomes in pediatric nonmetastatic osteosarcoma.

Dr Wilky on a Study of Botensilimab Plus Balstilimab in Refractory Metastatic Sarcoma

September 13th 2024

Breelyn Wilky, MD, discusses updated findings from a phase 1 study investigating botensilimab plus balstilimab in refractory metastatic sarcoma.